CTLA4 and prostate carcinoma: Inhibition of CTLA-4 has been utilized to promote anti-tumour immunity: ipilimumab, a fully human monoclonal antibody (IgG1) that inhibits CTLA-4, is widely used in the treatment of malignant melanoma and prostate cancer [9].